Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2022
DBVT released its monthly report on voting rights and share count as of January 31, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
Positive
- Transparency in reporting voting rights and share count may boost investor confidence.
- Total shares increased to 55,095,762, indicating potential company growth.
Negative
- None.
Details
News Market Reaction – DBVT
The recorded move for DBVT in the trading session of this news was -2.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Monthly information regarding the total number of voting rights and
total number of shares of the Company as of January 31, 2022
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market: NYSE Euronext Paris
ISIN Code: FR 0010417345
Date | Total number of shares | Total number of voting rights |
| 01/31/2022 | 55,095,762 | Total gross of voting rights: 55,095,762 |
Total net* of voting rights: 54,925,155 |
* Total net = total number of voting rights attached to shares – shares without voting rights
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.